In JoVE (1)
Articles by Joshua Ejdelman in JoVE
Preparation of Formalin-fixed Paraffin-embedded Tissue Cores for both RNA and DNA Extraction Palak G. Patel1,2, Shamini Selvarajah1,2, Suzanne Boursalie1,2, Nathan E. How1,2, Joshua Ejdelman3, Karl-Philippe Guerard3, John M. Bartlett4, Jacques Lapointe3, Paul C. Park1, John B. A. Okello1,2, David M. Berman1,2 1Department of Pathology & Molecular Medicine, Queen's University, 2Division of Cancer Biology & Genetics, Queen's Cancer Research Institute, Queen's University, 3Department of Surgery, Division of Urology, McGill University, 4Transformative Pathology Program, Ontario Institute for Cancer Research (OICR) This modified extraction protocol improves RNA and DNA yields from more precisely targeted regions of interest in histopathologic tissue blocks.
Other articles by Joshua Ejdelman on PubMed
PTEN Genomic Deletion Predicts Prostate Cancer Recurrence and is Associated with Low AR Expression and Transcriptional Activity BMC Cancer. 2012 | Pubmed ID: 23171135 Prostate cancer (PCa), a leading cause of cancer death in North American men, displays a broad range of clinical outcome from relatively indolent to lethal metastatic disease. Several genomic alterations have been identified in PCa which may serve as predictors of progression. PTEN, (10q23.3), is a negative regulator of the phosphatidylinositol 3-kinase (PIK3)/AKT survival pathway and a tumor suppressor frequently deleted in PCa. The androgen receptor (AR) signalling pathway is known to play an important role in PCa and its blockade constitutes a commonly used treatment modality. In this study, we assessed the deletion status of PTEN along with AR expression levels in 43 primary PCa specimens with clinical follow-up.
The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression Translational Oncology. Dec, 2012 | Pubmed ID: 23401739 Prostate cancer (PCa) is a leading cause of cancer death, and distinguishing aggressive from indolent tumors is a major challenge. Identification and characterization of genomic alterations associated with advanced disease can provide new markers of progression and better therapeutic approaches.